BRD4 and Burkitt lymphoma: Although traditional small-molecule BRD4 inhibitors have shown promise in the treatment of Myc-driven cancers such as Burkitt’s lymphoma (BL), their use often leads to accumulation of the BRD4 protein, which results in limited suppression of Myc expression, low antiproliferative activity and no induction of apoptosis.